Please note, this OEL/ADE monograph also applies to pazufloxacin base (CAS RN 127045-41-4). Pazufloxacin has shown a multimodal mechanism of action and inhibits both DNA gyrase and topoisomerase IV enzyme, leading to increased antibacterial spectrum. Moreover, pazufloxacin has been shown to also have DNA antagonistic actions. The multimodal mechanism of action is linked to the low potential for the development of resistance in pazufloxacin. It has been shown that pazufloxacin is not affected by efflux mechanism of resistance.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:
To order an OEL/ADE monograph for Pazufloxacin Methanesulfonate, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.